A groundbreaking study has revealed that a significant number of breast cancer patients might be able to forgo chemotherapy, thanks to a new DNA test designed to assess their likelihood of benefitting from the treatment. Conducted by researchers at University College London (UCL), this international trial indicates that over two-thirds of participants could avoid the harsh side effects associated with chemotherapy, opting instead for hormone therapy.
Study Overview
The research, which involved more than 4,000 newly diagnosed individuals aged 40 and over from countries including the UK, Norway, Sweden, Australia, New Zealand, and Thailand, marks a pivotal advancement in breast cancer treatment protocols. The study utilised a gene test known as Prosigna, which evaluates the activity of 50 genes associated with breast cancer progression. By calculating a patient’s risk of recurrence based on their genetic makeup, the test identifies those who would not benefit from chemotherapy.
The findings are striking: approximately 67% of participants received a low risk score, leading to the recommendation of hormone therapy alone. The five-year survival rate for this group stood at an impressive 93.7%, compared to 94.9% for those who underwent chemotherapy. This suggests that the test could significantly change the landscape of breast cancer treatment, sparing many from the often debilitating effects of chemotherapy.
Implications for Treatment Protocols
Traditionally, breast cancer treatment typically begins with surgery to remove tumours, followed by chemotherapy to reduce the risk of recurrence. However, the UCL study raises crucial questions about the necessity of chemotherapy for many patients, particularly those with early-stage cancer and no lymph node involvement.
Professor David Miles, a prominent cancer specialist involved in the study, labelled the findings as “practice-changing.” He highlighted the test’s potential to identify a substantial patient population that does not require chemotherapy, thereby preventing unnecessary suffering. “We used to administer chemotherapy to 100 women, knowing only 10 would benefit; now we can avoid that,” he remarked.
The study also suggests that more than 5,000 patients treated by the NHS each year could potentially avoid chemotherapy, a significant statistic for healthcare planning and patient care.
Patient Perspectives
The results have provided hope and relief for many participants. Karen Bonham, a 64-year-old from Cardiff who took part in the trial, expressed her gratitude, stating that the outcomes felt like “an immense relief” and “like Christmas.” Having avoided chemotherapy, she instead underwent radiotherapy and hormone therapy, allowing her to manage her condition without the severe side effects associated with cancer treatment.
Conversely, Tanya Hutson, diagnosed with breast cancer in 2022, reflected on her chemotherapy experience as “brutal.” She praised the new DNA test as an “absolute game changer,” emphasising the importance of research funding in improving patient outcomes. “For all these people out there who don’t need it but are still getting it—this test is revolutionary,” she affirmed.
Future Considerations
Despite the promising results, there remains uncertainty regarding the applicability of the findings to individuals under the age of 40. UCL researchers have indicated that further studies will be necessary to determine how the test performs across different age demographics, with results expected in the coming years.
The findings are set to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago, an event renowned for shaping future cancer treatment strategies.
Why it Matters
The implications of this study extend beyond individual patient care; they could redefine the standard approach to breast cancer treatment worldwide. As we move towards more personalised medicine, the ability to tailor treatment based on genetic information not only holds the promise of better health outcomes but also enhances the quality of life for countless patients. By potentially sparing thousands from the burdens of chemotherapy, this research underscores the critical need for ongoing investment in cancer research and the development of innovative diagnostic tools.
